TuHURA Biosciences (HURA) 10-Q 12 Nov 20 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2020	Nov. 09, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	KTRA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		24,662,299
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	12707 High Bluff Dr.
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	858
Local Phone Number	350-4364
Document Transition Report	false

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Current assets
Cash and cash equivalents	$ 22,602,000	$ 2,392,000
Prepaid expenses and deposits	343,000	356,000
Interest, taxes and other receivables	10,000	9,000
Deferred loan costs		94,000
Current assets	22,955,000	2,851,000
Intangible assets - net	1,000	2,000
Property and equipment	175,000
Deferred financing costs		85,000
Total assets	23,131,000	2,938,000
Current liabilities
Accounts payable and accrued liabilities	1,566,000	2,011,000
Loan payable, net of deferred loan costs	441,000
Related party payables	382,004	663,865
Current liabilities	2,389,000	2,675,000
Milestone payment liability	188,000
Total liabilities	2,577,000	2,675,000
Stockholders’ equity
Common stock Authorized 95,000 shares at September 30, 2020 and June 30, 2020, $0.001 par value 24,466 issued at September 30, 2020 (June 30, 2020 – 11,458)	24,000	11,000
Additional paid-in capital	89,777,000	65,148,000
Accumulated deficit	(92,427,000)	(69,721,000)
Accumulated other comprehensive income	21,000	21,000
Total stockholders’ equity	20,554,000	263,000
Total liabilities and stockholders’ equity	23,131,000	2,938,000
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279,000	279,000
Preferred Stock Series B
Stockholders’ equity
Preferred stock	4,525,000	$ 4,525,000
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 18,355,000

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	24,466,000	11,458,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Preferred Stock Series B
Preferred Stock, shares issued	649,000	649,000
Preferred stock, shares outstanding	648,613	648,613
Preferred Stock Series C
Preferred Stock, shares issued	25,000	0
Preferred stock, shares outstanding	25,028	0

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Expenses
Research and development	$ 1,357	$ 721
General and administrative	1,534	914
Merger costs	500
In-process research and development	16,094
Operating Expenses	19,485	1,635
Other (income) loss
Foreign exchange loss	(1)
Amortization of deferred loan costs	27
Interest expense	8
Interest income	(1)	(29)
Other loss (income)	33	(29)
Net loss for the period	19,518	1,606
Computation of basic loss per share
Net loss for the period	19,518	1,606
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance	3,181
Series A Preferred cash dividend	2	2
Series B Preferred stock dividend	5	2
Net loss for the period attributable to common stockholders	$ 22,706	$ 1,610
Basic and fully diluted loss per share	$ 1.33	$ 0.21
Basic and fully diluted weighted average number of shares	17,106,000	7,539,000

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders' Equity (Unaudited) - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2019	$ 1,968,000	$ 4,000	$ 57,543,000	$ 21,000	$ 4,978,000	$ (60,578,000)
Beginning Balance, shares at Jun. 30, 2019		3,839,000
Issuance of shares and warrants - net ofissue costs	6,583,000	$ 5,000	6,578,000
Issuance of shares and warrants - net of issue costs, shares		4,895,000
Exercise of pre-funded warrants for cash	26,000	$ 2,000	24,000
Exercise of pre-funded warrants for cash, shares		2,655,000
Conversion of Series B preferred stockto common stock			174,000		(174,000)
Conversion of Series B preferred stock to common stock, shares		6,000
Shares issued for services	5,000	$ 4,843	5,000
Shares issued for services, shares		6,925
Stock option expense	51,000		51,000
Series A Preferred cash dividend	(2,000)					(2,000)
Series B Preferred stock dividend			2,000			(2,000)
Series B preferred stock dividend, shares		4,000
Loss for the period	(1,606,000)					(1,606,000)
Ending Balance at Sep. 30, 2019	7,025,000	$ 11,000	64,377,000	21,000	4,804,000	(62,188,000)
Ending Balance, shares at Sep. 30, 2019		11,406,000
Beginning Balance at Jun. 30, 2019	1,968,000	$ 4,000	57,543,000	21,000	4,978,000	(60,578,000)
Beginning Balance, shares at Jun. 30, 2019		3,839,000
Ending Balance at Jun. 30, 2020	263,000	$ 11,000	65,148,000	21,000	4,804,000	(69,721,000)
Ending Balance, shares at Jun. 30, 2020		11,458,000
Adgero merger (note 3)	16,725,000	$ 12,000	16,713,000
Adgero merger, shares		12,011,000
Issuance of Series C Preferred stock	25,028,000				25,028,000
Series C placement agent warrants			3,287,000		(3,287,000)
Series C Preferred stock share issuance costs	(3,386,000)				(3,386,000)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance			3,181,000			(3,181,000)
Exercise of warrants for cash	994,000	$ 1,000	993,000
Exercise of warrants for cash, shares		993,000
Warrants issued for services	45,000		45,000
Shares issued for services		$ 0
Shares issued for services, shares		0
Stock option expense	405,000		405,000
Series A Preferred cash dividend	(2,000)					(2,000)
Series B Preferred stock dividend			5,000			(5,000)
Series B preferred stock dividend, shares		4,000
Loss for the period	(19,518,000)					(19,518,000)
Ending Balance at Sep. 30, 2020	$ 20,554,000	$ 24,000	$ 89,777,000	$ 21,000	$ 23,159,000	$ (92,427,000)
Ending Balance, shares at Sep. 30, 2020		24,466,000

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Loss for the period	$ (19,518)	$ (1,606)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets	1	3
In-process research and development	16,094
Amortization of deferred loan costs	27
Interest expense	8
Shares issued for services		5
Warrants issued for services	45
Stock option expense	405	51
Changes in operating assets and liabilities
Prepaid expenses and deposits	24	56
Interest, taxes and other receivables		(44)
Accounts payable and accrued liabilities	(914)	(617)
Related party payables	(282)	(114)
Net cash used in operating activities	(4,110)	(2,266)
Cash flows from investing activities
Cash acquired on merger with Adgero	969
Net cash provided by investing activities	969
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	21,859	6,583
Warrants exercised for cash	994	26
Proceeds from loan	500
Series A preferred cash dividend	(2)	(2)
Net cash provided by financing activities	23,351	6,607
Decrease in cash and cash equivalents	20,210	4,341
Cash and cash equivalents – beginning of period	2,392	3,719
Cash and cash equivalents – end of period	$ 22,602	$ 8,060

Nature of operations, corporate

Nature of operations, corporate history, and liquidity risk and management plans	3 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of operations, corporate history, and liquidity risk and management plans	1 Nature of operations, corporate history, and liquidity risk and management plans Nature of operations Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (the “Company”) is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. On June 9, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Adgero Acquisition Corp., the Company’s wholly-owned subsidiary incorporated in the State of Delaware (“Merger Sub”), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”). On August 19, 2020, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into Adgero (the “Merger”), the separate corporate existence of Merger Sub ceased and Adgero continued its existence under Delaware law as the surviving corporation in the Merger and became a direct, wholly-owned subsidiary of the Company. As a result of the Merger, each issued and outstanding share of Adgero common stock, par value $0.0001 per share (the “Adgero Common Stock”) (other than treasury shares held by Adgero), was converted automatically into the right to receive 1.5740 shares (the “Exchange Ratio”) of the Company’s common stock, and cash in lieu of any fractional shares. Also, each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of the Company’s common stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio. Following the completion of the Merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on Nasdaq under the symbol “KTRA”. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero. References to the Company refer to the Company and its wholly-owned subsidiaries. Liquidity risk and management plans During the three months ended September 30, 2020, the Company reported a net loss of $19.5 million. As of September 30, 2020, the Company had $22.6 million of cash and cash equivalents and used $4.1 million of cash in its operating activities during the three months ended September 30, 2020. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. In the future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. The Company may tailor its drug development programs based on the amount of funding the Company is able to raise in the future. During the three months ended September 30, 2020, the Company completed a private placement in three closings for aggregate net proceeds of approximately $21.6 million (note 6). The Company believes that based on its current estimates, the cash and cash equivalents at September 30, 2020 of $22.6 million, as well as cash from the proceeds from stock purchase warrants exercised subsequent to September 30, 2020, will be sufficient to fund its planned operations for at least the next twelve months from the date these condensed consolidated interim financial statements are issued. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. The ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital in the future is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Certain prior period balances have been reclassified to conform with the current period’s presentation. Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2020 included in our Form 10-K. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three months ended September 30, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2021, or for any other future annual or interim period. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the three-month periods ended September 30, 2020 and 2019 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares is anti-dilutive. As of September 30, 2020, potential common shares of 11,858,152 (2019 – 9,683,596) related to outstanding common share warrants, 2,152,701 (2019 – nil) related to outstanding Series C preferred stock warrants, 6,543,569 (2019 – 780,000) related to stock options, 162,177 (2019 – 162,177) relating to outstanding Series B convertible preferred shares, and 21,516,484 (2019 – nil) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero. As the acquired in-process research and development assets were deemed to have no current or alternative future use, an expense of $16.1 million was recognized in the condensed consolidated interim statements of operations for the three month period ended September 30, 2020. Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of five years. Depreciation expense is recognized from the date the equipment is put into use. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Not yet adopted Accounting Standards Update (“ASU”) 2020-06 — Debt - Debt with conversion and other options (subtopic 470-20) and derivatives and hedging – contracts in entity’s own equity (subtopic 815-40): accounting for convertible instruments and contracts in an entity’s own equity The amendments in this update are intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. For public business entities that are not smaller reporting companies, the ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. For all other entities, the effective date is for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has not yet evaluated the impact of adoption of this ASU on its condensed consolidated interim financial statements and related disclosures. During the three-months ended September 30, 2020, other than ASU 2020-06 there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

Merger

Merger	3 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Merger	1 Merger As described in Note 1, on August 19, 2020, the Company completed its Merger with Adgero in accordance with the terms of the Merger Agreement. To determine the accounting for this transaction under ASU 2017-01, an assessment must be made as to whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the set is not a business. In connection with the Merger, substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). As such, the Merger has been treated as an acquisition of Adgero assets and an assumption of Adgero liabilities. Under the terms of the Merger Agreement, upon closing of the Merger, the Company issued 11,439,013 shares of Company common stock and 2,313,904 stock purchase warrants to the security holders of Adgero (“Adgero Warrants”). The Adgero Warrants are exercisable at $3.18 per share (note 6). The Adgero Warrants were valued using a Black-Scholes valuation with a weighted-average risk-free interest rate of 0.21%, a term of one year, a The Company incurred approximately $1.55 million of legal, consulting and other professional fees related to the Merger, of which approximately $1.1 million had been incurred in the year ended June 30, 2020. The transaction costs have been classified as merger expenses in the accompanying unaudited condensed consolidated interim statement of operations for the three months ended September 30, 2020. The following summarizes total consideration transferred to the Adgero stockholders under the Merger as well as the assets acquired and liabilities assumed under the Merger: $ (in thousands) Consideration: Common stock 15,328 Warrants 630 Success fee shares 766 16,724 Net assets acquired: Cash (969 ) Other current assets (11 ) Property and equipment (175 ) Accounts payable and accrued liabilities 337 Milestone payment liability 188 In-process research and development 16,094 Property and equipment include office furniture that was subsequently sold and laboratory equipment that has not yet been put into use. The milestone payment liability relates to an asset purchase agreement with St. Cloud Investments, LLC (“St. Cloud”) that Adgero has regarding the acquisition of REM-001. The Agreement, as amended, is dated November 26, 2012 (the “St. Cloud Agreement”). Pursuant to the terms of the St. Cloud Agreement, the Company is obligated to make certain payments under the agreement. The future contingent amounts payable under that agreement are as follows: • Upon the earlier of (i) a subsequent equity financing to take place after the Company conducts a Phase 2B clinical study in which fifty patients complete the study and their clinical data can be evaluated or (ii) the commencement of a clinical study intended to be used as a definitive study for market approval in any country, the Company is obligated to pay an aggregate amount of $300,000 in cash or an equivalent amount of common stock, with $240,000 to St. Cloud and $60,000 to an employee of the Company; and • Upon receipt of regulatory approval of REM-001 Therapy, the Company is obligated to pay an aggregate amount of $700,000 in cash or an equivalent amount of common stock, with $560,000 to St. Cloud and $140,000 to an employee of the Company. With respect to the $300,000 and $700,000 potential milestone payments referenced above (each a “Milestone Payment”), if either such Milestone Payment becomes payable, and in the event the Company elects to pay either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above. The milestone payment liability has been determined using the discounted cash flow value of the two respective milestone payments. A discount rate of 79% has been used which accounts for the probability of success given the phase of clinical development of REM-001. The term is based on an estimate of the planned timing of completion of the respective milestones that would result in payment of the milestones. The fair value of the IPR&D assets is expensed as a charge in the condensed consolidated interim statements of operations for the three months ended September 30, 2020 as there is no alternative use for these assets.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related party transactions	4 Related party transactions Valent Technologies, LLC Agreements One of the Company’s officers is a principal of Valent Technologies, LLC (“Valent”) and as result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for the drug’s further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate accrued interest to September 30, 2014 of $28,530), issued to Valent by Del Mar (BC), for 278,530 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the three months ended September 30, 2020 and 2019 respectively, the Company recorded $2,089 related to the dividend paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. Related party payables At September 30, 2020 there is an aggregate amount of $382,004 (June 30, 2020 - $663,865) payable to the Company’s officers and directors for fees, expenses, and accrued liabilities.

Loan from National Brain Tumor

Loan from National Brain Tumor Society and National Foundation for Cancer Research	3 Months Ended
	Sep. 30, 2020
Loans Payable [Abstract]
Loan from National Brain Tumor Society and National Foundation for Cancer Research	5 Loan from National Brain Tumor Society and National Foundation for Cancer Research $ (in thousands) Balance – June 30, 2020 — Funding 500 Financing costs (94 ) Interest expense 8 Amortization of deferred financing costs 27 Balance – September 30, 2020 441 During the period ended September 30, 2020, the Company received a loan of $500,000 from National Brain Tumor Society (“NBTS”) and the National Foundation for Cancer Research to support VAL-083's preparation for participation in the Global Coalition for Adaptive Research's (“GCAR”) sponsored trial, Glioblastoma (“GBM”) Adaptive Global Innovative Learning Environment (“GBM AGILE”) study (the “NBTS Loan”). In relation to the NBTS Loan, the Company issued 125,000 share purchase warrants which are exercisable at a price of $1.09 per common share until June 19, 2025 and had been included in deferred financing costs as at June 30, 2020 (“NBTS Warrants”). The NBTS Loan is secured by a promissory note, accrues interest at a rate of 6% per annum and matures on June 19, 2021. The NBTS Warrants were valued at $93,701 using a Black-Scholes valuation with a risk-free interest rate of 0.37%, a term of 5 years, a volatility of 89.82%, and a dividend rate of 0%. The estimated volatility of the Company’s common stock at the date of measurement is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the instrument at the valuation date. The expected term has been estimated using the remaining life of the warrant.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	6 Stockholders’ equity Preferred stock Series C Preferred stock Series C Preferred Stock Number of shares $ (in thousands) Balance – June 30, 2020 — — Issuance 25,028 18,355 Balance – September 30, 2020 25,028 18,355 In connection with the Merger (note 3), the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3) in August, 2020. Each share of Series C Preferred Stock was issued at a purchase price of $1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. Subject to ownership limitations, the owners of the Series C Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10%, 15%, 20% and 25% of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12 th th th th The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series C-3 Preferred Stock are $1.16, $1.214 and $1.15, respectively. Based on the conversion prices of the three respective classes of the Series C Preferred Stock, the 25,028 shares of Series C Preferred Stock will be convertible into an aggregate of 21,516,484 shares of common stock. The cumulative dividends to be issued on the 12 th th th th The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $3.18 million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share. The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock shall be pari passu in liquidation to the Company’s Series A and Series B Preferred Stock. The liquidation value of the Series C Preferred Stock at September 30, 2020 is the stated value of $25,028,000. Total gross proceeds from the private placement were $25 million, or $21.6 million in net proceeds after deducting financing costs of $3.4 million with respect to agent commissions and expenses, as well as legal and accounting fees. Of the total financing costs, $84,944 was deferred as of June 30, 2020. In addition, the Company issued warrants to purchase 2,504 shares of Series C Stock to the placement agent (“2020 Agent Warrants”) that are convertible into an aggregate 2,152,701 shares of common stock. A total of 25,028 (June 30, 2020 – Nil) shares of Series C Preferred Stock are outstanding as of September 30, 2020, such that a total of 21,516,484 (June 30, 2020 – Nil) shares of common stock are issuable upon conversion of the Series C Preferred Stock as at September 30, 2020. Converted shares are rounded up to the nearest whole share. Series B Preferred Stock During the year ended June 30, 2016, the Company issued an aggregate of 902,238 shares of Series B Preferred Stock at a purchase price of $8.00 per share. Each share of Series B Preferred Stock is convertible into 0.25 shares of common stock equating to a conversion price of $32.00 (the “Conversion Price”) and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $80.00, or five years from the respective final closing dates. The holders of the Series B Preferred Stock are entitled to an annual cumulative, in arrears, dividend at the rate of 9% payable quarterly. The 9% dividend accrues quarterly commencing on the date of issue and is payable quarterly on September 30, December 31, March 31, and June 30 of each year commencing on June 30, 2016. Dividends are payable solely by delivery of shares of common stock, in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the Conversion Price. The Series B Preferred Stock does not contain any repricing features. Each share of Series B Preferred Stock entitles its holder to vote with the common stock on an as-converted basis. The Series B Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series B Preferred Stock. The Series B Preferred Stock shall be pari passu in liquidation to the Company’s Series A and Series C Preferred Stock. The liquidation value of the Series B Preferred Stock at September 30, 2020 is the stated value of $5.2 million (June 30, 2020 - $5.2 million). In addition, the Company and the holders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B Preferred Stock, in aggregate, a low, single-digit royalty based on their pro rata ownership of the Series B Preferred Stock on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the “Royalty Agreement”). Upon conversion of a holder’s Series B Preferred Stock to common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon which vesting dates such royalty amounts shall become vested royalties. Pursuant to the Series B Preferred Stock dividend, during the three months ended September 30, 2020, the Company issued 3,700 (2019 – 3,700) shares of common stock and recognized $5,180 (2019 – $2,046) as a direct increase in accumulated deficit. During the three months ended September 30, 2020 there were no conversions (2019 - 25,000) of Series B Preferred Stock for nil (2019 – 6,250) shares of common stock. A total of 648,613 (June 30, 2020 – 648,613) shares of Series B Preferred Stock are outstanding as of September 30, 2020, such that a total of 162,177 (June 30, 2020 – 162,177) shares of common stock are issuable upon conversion of the Series B Preferred Stock as at September 30, 2020. Converted shares are rounded up to the nearest whole share. Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 4). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock shall be pari passu in liquidation to the Company’s Series B and Series C Preferred Stock. The liquidation value of the Series A Preferred stock at September 30, 2020 and June 30, 2020 was $278,530. There was no change to the Series A Preferred stock for the three months ended September 30, 2020 or 2019. Common stock Stock Issuances Three months ended September 30, 2019 Underwritten public offering On August 16, 2019, the Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock (“2020 Investor Warrants”), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant. The net proceeds from the Offering, including from the partial exercise of the underwriters’ option to purchase additional securities, were $6,582,966 after deducting underwriting discounts and commissions, and other offering expenses. The 2020 Investor Warrants are exercisable at $1.00 per share until their expiry on August 16, 2024 and the PFW are exercisable at $0.01 per share at any time after August 16, 2019. The Company also issued 377,500 warrants to the underwriters of the Offering. The underwriter warrants are exercisable at $1.15 per share commencing February 10, 2020 until their expiry on August 14, 2022. During the three months ended September 30, 2019, all of the 2,655,000 PFW were exercised at $0.01 per PFW for proceeds of $26,550. Shares issued for services During the three months ended September 30, 2020, the Company issued Nil (2019 – 6,925) shares of common stock for services resulting in the recognition of $Nil (2019 – $4,843) in expense. All of the shares issued for services for the three months ended September 30, 2019 have been recognized as research and development expense. 2017 Omnibus Incentive Plan The Company’s board of directors has approved adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”) that has also been approved by the Company’s stockholders. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) under the 2017 Plan. Under the 2017 Plan, 6,700,000 shares of Company common stock are currently reserved for issuance, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”) or that are subject to grants of stock options made, or that may be made, under the Legacy Plan. As of September 30, 2020, a total of 164,235 shares of common stock are currently outstanding under the Legacy Plan and/or are subject to outstanding stock options granted under the Legacy Plan, and a total of 6,379,334 shares of common stock have been issued under the 2017 Plan and/or are subject to outstanding stock options granted under the 2017 Plan leaving 156,431 shares of common stock available at September 30, 2020 for issuance under the 2017 Plan if all such options under the Legacy Plan were exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8% of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on or after July 7, 2027, but awards granted prior to that date may extend beyond that date. During the three months ended September 30, 2020, a total of 222,584 stock options issued to directors of the Company were amended such that the period to exercise vested stock options from the date of termination of continuous service with the Company was extended from 90 days to one year. Of the total of 222,584, 66,850 had their expiry increased from September 26, 2020 to June 26, 2021 and 155,734 had their expiry increased from November 19, 2020 to August 19, 2021. As a result of the amendments, a total of $8,569 stock-based compensation expense has been recognized. In addition, 250,000 stock options previously granted to an officer of the Company were amended such that the vesting of the stock options was changed from a completely contingent vesting to a time-based vesting such that 1/6 th During the three months ended September 30, 2020, a total of 4,758,687 stock options were granted to executive officers and directors of the Company. Of these, 4,698,687 have an exercise price of $1.70 per share and 60,000 have an exercise price of $1.355 per share. Of the total granted, 4,278,687 stock options vest as to 1/6 on the six month anniversary of the grant date with the remaining portion vesting in equal monthly installments over a period of 30 months commencing on the seven month anniversary of the grant date. Of the total stock options granted to executive officers and directors, 480,000 vest in 12 equal monthly installments beginning on October 15, 2020. All of the stock options granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. Stock Options The following table sets forth changes in stock options outstanding under all plans: Number of stock options outstanding (in thousands) Weighted average exercise price Balance – June 30, 2020 1,559 4.61 Granted 4,999 1.68 Forfeited (14 ) 1.42 Balance – September 30, 2020 6,544 2.38 The following table summarizes stock options outstanding and exercisable under all plans at September 30, 2020: Exercise price $ Number Outstanding at September 30, 2020 (in thousands) Weighted average remaining contractual life (years) Number exercisable at September 30, 2020 (in thousands) 0.61 1,010 8.93 566 0.74 250 9.12 — 1.36 300 9.98 — 1.70 4,699 9.96 — 6.10 30 8.11 26 7.00 3 7.73 3 8.70 12 7.09 12 9.83 83 7.64 65 10.60 4 7.54 3 11.70 30 2.41 30 14.94 3 1.67 3 20.00 13 1.02 13 21.10 14 6.77 14 29.60 5 4.35 5 37.60 5 5.36 5 41.00 4 6.11 4 42.00 41 2.31 41 44.80 3 5.36 3 49.50 22 3.82 22 53.20 8 5.60 8 61.60 2 2.50 2 92.00 3 2.67 3 6,544 828 Included in the number of stock options outstanding are 2,500 stock options granted at an exercise price of CA$20.00. The exercise price of these options shown in the above table have been converted to US$14.94 using the period ending closing exchange rate. Stock options granted during the three months ended September 30, 2020 have been valued using a Black-Scholes pricing model with the following assumptions: September 30, 2020 Dividend rate — % Volatility 121% to 153 % Risk-free rate 0.19% to 0.42 % Term – years 0.4 to 5.8 The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the stock options at the valuation date. The expected life of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted (in thousands): Three months ended September 30, 2020 $ 2019 $ Research and development 91 8 General and administrative 314 43 405 51 All of the stock option expense for the periods ended September 30, 2020 and 2019 has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding at September 30, 2020 was $977,465 (2019 - $0) and the aggregate intrinsic value of stock options exercisable at September 30, 2020 was $446,950 (2019 - $0). As of September 30, 2020, there was $7,802,208 in unrecognized compensation expense that will be recognized over the next 3.0 years. No stock options granted under the Company’s equity plans have been exercised during the three months ended September 30, 2020. Upon the exercise of stock options new shares will be issued. The following table sets forth changes in unvested stock options under all plans: Number of Options (in thousands) Weighted average exercise price $ Unvested at June 30, 2020 858 0.98 Granted 4,999 1.68 Vested (127 ) 1.18 Forfeited (14 ) 1.42 Unvested at September 30, 2020 5,716 1.59 The aggregate intrinsic value of unvested stock options at September 30, 2020 was $530,516 (2019 - $0). The unvested stock options have a remaining weighted average contractual term of 9.83 (2019 – 9.76) years. Common Stock Warrants The following table sets forth changes in outstanding common stock warrants: Number of Warrants (in thousands) Weighted average exercise price $ Balance – June 30, 2020 10,309 2.71 Issuance of Adgero Warrants 2,314 3.18 Exercise of warrants (i) (994 ) 1.00 Warrants issued for services (ii) 330 1.49 Expiry of warrants (iii) (101 ) 30.00 Balance – September 30, 2020 11,858 2.67 i) A total of 994,000 2020 Investor Warrants were exercised at $1.00 per share. ii) Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below. i ii ) The warrant expiries include the The following table summarizes the Company’s outstanding common stock warrants as of September 30, 2020: Description of warrants Number (in thousands) Exercise price $ Expiry date 2020 Investor warrants 6,744 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2019 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants 125 1.09 June 19, 2025 (i) Warrants issued for services 25 30.00 December 1, 2020 to February 1, 2021 Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 14 9.00 September 15, 2023 and October 11, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 250 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 2020 Underwriter Warrants 377 1.15 August 14, 2022 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 2016 Agent warrants 10 40.00 May 12, 2021 Adgero Warrants 1,206 3.18 April 8, 2021 Adgero Warrants 353 3.18 August 31, 2021 Adgero Warrants 755 3.18 January 17, 2022 11,858 (i) NBTS Warrants were issued in connection with respect to the NBTS Loan (note 5). Series C Preferred Stock Warrants In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Stock purchase warrants (the “Series C Warrants”). The Series C Warrants have an exercise price of $1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Warrants is convertible into shares of common stock in the same manner as each respective series of outstanding Series C Stock, and will be entitled to the same dividend rights as each respective series. The 2020 Agent Warrants were valued at a total of approximately $3.3 million using a binomial pricing model with a risk-free interest rate of 0.27%, a term of 4.0 years, and a volatility of 95.2% to 95.8%. The estimated volatility of the Company’s common stock at the date of measurement is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the instrument at the valuation date. The expected term has been estimated using the contractual term of the warrant. The following table sets forth changes in outstanding Series C Warrants: Number of Warrants Conversion price $ Balance – June 30, 2020 — Issuance of Preferred Series C-1 Warrants 1,959 1.16 Issuance of Preferred Series C-2 Warrants 219 1.21 Issuance of Preferred Series C-3 Warrants 326 1.15 Balance – September 30, 2020 2,504 The following table summarizes the Company’s outstanding Series C Warrants as of September 30, 2020: Description of warrants Number Conversion price $ Number of conversion shares (in thousands) Cumulative common stock dividends (in thousands) Series 1 1,959 1.16 1,689 1,182 Series 2 219 1.21 180 126 Series 3 326 1.15 283 198 2,504 2,152 1,506

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	3 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	7 Supplementary statement of cash flows information The Company incurred the following non-cash investing and financing transactions (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Series B Preferred Stock common stock dividend (note 6) 5 2 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6) 3,181 — Non-cash issue costs (note 6) 3,287 — Issue costs in accounts payable (note 6) 193 — Income taxes paid — — Interest paid — —

Financial instruments

Financial instruments	3 Months Ended
	Sep. 30, 2020
Investments All Other Investments [Abstract]
Financial Instruments	8 Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and loan payable. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. The fair value of the loan payable is equal to its principal and accrued interest of $508,466 as at September 30, 2020.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent events	9 Subsequent events Warrant exercises Subsequent to September 30, 2020, 161,084 Stock option exercises Subsequent to September 30, 2020, 35,000 stock options were exercised at $0.61 per share for gross proceeds of $21,350. Stock option amendments On November 11, 2020, the Board of Directors approved the acceleration of vesting of 279,675 stock options to purchase shares of the Company’s common stock previously granted on September 5, 2019 to an executive officer of the Company. The exercise price of the stock options is $0.61 per share The Company has evaluated its subsequent events from September 30, 2020 through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Certain prior period balances have been reclassified to conform with the current period’s presentation.
Unaudited Interim Financial Data Policy	Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements of the Company as at June 30, 2020 included in our Form 10-K. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three months ended September 30, 2020 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2021, or for any other future annual or interim period.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.
Loss Per Share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the three-month periods ended September 30, 2020 and 2019 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares is anti-dilutive. As of September 30, 2020, potential common shares of 11,858,152 (2019 – 9,683,596) related to outstanding common share warrants, 2,152,701 (2019 – nil) related to outstanding Series C preferred stock warrants, 6,543,569 (2019 – 780,000) related to stock options, 162,177 (2019 – 162,177) relating to outstanding Series B convertible preferred shares, and 21,516,484 (2019 – nil) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Acquired In-process Research And Development Expense	Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero. As the acquired in-process research and development assets were deemed to have no current or alternative future use, an expense of $16.1 million was recognized in the condensed consolidated interim statements of operations for the three month period ended September 30, 2020.
Property, Plant and Equipment, Policy	Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of five years. Depreciation expense is recognized from the date the equipment is put into use.
Recent Accounting Pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Not yet adopted Accounting Standards Update (“ASU”) 2020-06 — Debt - Debt with conversion and other options (subtopic 470-20) and derivatives and hedging – contracts in entity’s own equity (subtopic 815-40): accounting for convertible instruments and contracts in an entity’s own equity The amendments in this update are intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. For public business entities that are not smaller reporting companies, the ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. For all other entities, the effective date is for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has not yet evaluated the impact of adoption of this ASU on its condensed consolidated interim financial statements and related disclosures. During the three-months ended September 30, 2020, other than ASU 2020-06 there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

Merger (Tables)

Merger (Tables)	3 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Schedule of Consideration Transferred Stockholders, Recognized Identified Assets Acquired and Liabilities Assumed Under Merger	The following summarizes total consideration transferred to the Adgero stockholders under the Merger as well as the assets acquired and liabilities assumed under the Merger: $ (in thousands) Consideration: Common stock 15,328 Warrants 630 Success fee shares 766 16,724 Net assets acquired: Cash (969 ) Other current assets (11 ) Property and equipment (175 ) Accounts payable and accrued liabilities 337 Milestone payment liability 188 In-process research and development 16,094

Loan from National Brain Tumo_2

Loan from National Brain Tumor Society and National Foundation for Cancer Research (Tables)	3 Months Ended
	Sep. 30, 2020
Loans Payable [Abstract]
Summary of Loan	$ (in thousands) Balance – June 30, 2020 — Funding 500 Financing costs (94 ) Interest expense 8 Amortization of deferred financing costs 27 Balance – September 30, 2020 441

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2020
Class Of Stock [Line Items]
Schedule of Stock Option Expense	Three months ended September 30, 2020 $ 2019 $ Research and development 91 8 General and administrative 314 43 405 51
Schedule of Unvested Stock Options	Number of Options (in thousands) Weighted average exercise price $ Unvested at June 30, 2020 858 0.98 Granted 4,999 1.68 Vested (127 ) 1.18 Forfeited (14 ) 1.42 Unvested at September 30, 2020 5,716 1.59
Schedule of Warrants	Number of Warrants (in thousands) Weighted average exercise price $ Balance – June 30, 2020 10,309 2.71 Issuance of Adgero Warrants 2,314 3.18 Exercise of warrants (i) (994 ) 1.00 Warrants issued for services (ii) 330 1.49 Expiry of warrants (iii) (101 ) 30.00 Balance – September 30, 2020 11,858 2.67 i) A total of 994,000 2020 Investor Warrants were exercised at $1.00 per share. ii) Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below. i ii ) The warrant expiries include the
Schedule of Changes in Outstanding Warrants	Description of warrants Number (in thousands) Exercise price $ Expiry date 2020 Investor warrants 6,744 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2019 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants 125 1.09 June 19, 2025 (i) Warrants issued for services 25 30.00 December 1, 2020 to February 1, 2021 Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 14 9.00 September 15, 2023 and October 11, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 250 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 2020 Underwriter Warrants 377 1.15 August 14, 2022 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 2016 Agent warrants 10 40.00 May 12, 2021 Adgero Warrants 1,206 3.18 April 8, 2021 Adgero Warrants 353 3.18 August 31, 2021 Adgero Warrants 755 3.18 January 17, 2022 11,858 (i) NBTS Warrants were issued in connection with respect to the NBTS Loan (note 5).
Series C Warrants [Member]
Class Of Stock [Line Items]
Schedule of Changes in Outstanding Warrants	Description of warrants Number Conversion price $ Number of conversion shares (in thousands) Cumulative common stock dividends (in thousands) Series 1 1,959 1.16 1,689 1,182 Series 2 219 1.21 180 126 Series 3 326 1.15 283 198 2,504 2,152 1,506
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	Number of Warrants Conversion price $ Balance – June 30, 2020 — Issuance of Preferred Series C-1 Warrants 1,959 1.16 Issuance of Preferred Series C-2 Warrants 219 1.21 Issuance of Preferred Series C-3 Warrants 326 1.15 Balance – September 30, 2020 2,504
Stock options [Member]
Class Of Stock [Line Items]
Schedule of Outstanding Under the Legacy Plan	Number of stock options outstanding (in thousands) Weighted average exercise price Balance – June 30, 2020 1,559 4.61 Granted 4,999 1.68 Forfeited (14 ) 1.42 Balance – September 30, 2020 6,544 2.38
Summary of Stock Options Currently Outstanding and Exercisable	Exercise price $ Number Outstanding at September 30, 2020 (in thousands) Weighted average remaining contractual life (years) Number exercisable at September 30, 2020 (in thousands) 0.61 1,010 8.93 566 0.74 250 9.12 — 1.36 300 9.98 — 1.70 4,699 9.96 — 6.10 30 8.11 26 7.00 3 7.73 3 8.70 12 7.09 12 9.83 83 7.64 65 10.60 4 7.54 3 11.70 30 2.41 30 14.94 3 1.67 3 20.00 13 1.02 13 21.10 14 6.77 14 29.60 5 4.35 5 37.60 5 5.36 5 41.00 4 6.11 4 42.00 41 2.31 41 44.80 3 5.36 3 49.50 22 3.82 22 53.20 8 5.60 8 61.60 2 2.50 2 92.00 3 2.67 3 6,544 828
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model	September 30, 2020 Dividend rate — % Volatility 121% to 153 % Risk-free rate 0.19% to 0.42 % Term – years 0.4 to 5.8
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number of shares $ (in thousands) Balance – June 30, 2020 — — Issuance 25,028 18,355 Balance – September 30, 2020 25,028 18,355

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	3 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	The Company incurred the following non-cash investing and financing transactions (in thousands): Three months ended September 30, 2020 Three months ended September 30, 2019 Series B Preferred Stock common stock dividend (note 6) 5 2 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6) 3,181 — Non-cash issue costs (note 6) 3,287 — Issue costs in accounts payable (note 6) 193 — Income taxes paid — — Interest paid — —

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Liquidity Risk and Management Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Aug. 19, 2020	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Common stock, par value	$ 0.001		$ 0.0001	$ 0.001
Conversion of convertible common stock	1.5740 shares
Nature of operations, corporate history, and going concern (Textual)
Net loss	$ (19,518)	$ (1,606)
Cash flow from operations	(4,110)	$ (2,266)
Cash and cash equivalents	22,602			$ 2,392
Net proceeds from private placement	$ 21,600

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
In-process research and development	$ 16,094
Property and equipment estimated useful life	five years
Series C Preferred Share Warrants [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	2,152,701	0
Series B Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	162,177	162,177
Series C Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	21,516,484	0
Stock options [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	6,543,569	780,000
Warrant [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	11,858,152	9,683,596

Merger - Additional Information

Merger - Additional Information (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2020USD ($)Milestone$ / sharesshares	Jun. 30, 2020USD ($)	Aug. 19, 2020$ / shares
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Legal fee	$ 1,550	$ 1,100
Cash or equivalent to common stock	300,000
Contingent amounts payable to St. Cloud	240,000
Cash paid to employees	$ 60,000
Number of milestone | Milestone	2
Merger Agreement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Stock purchase warrants | shares	2,313,904
Warrants exercisable price | $ / shares	$ 3.18
Interest rate	0.21%
Weighted average remaining term	1 year
Volatility rate	115.96%
Dividend rate	0.00%
Merger success fee share price | $ / shares			$ 1.34
Merger Agreement [Member] | Common stock
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Number of shares issued | shares	11,439,013
Merger Agreement [Member] | Common stock | Private Placement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Merger success fee | shares	571,951
REM-001 Therapy [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Cash or equivalent to common stock	$ 700,000
Contingent amounts payable to St. Cloud	560,000
Cash paid to employees	$ 140,000
Discount rate	79.00%

Merger - Schedule of Considerat

Merger - Schedule of Consideration Transferred Stockholders, Recognized Identified Assets Acquired and Liabilities Assumed Under Merger (Details) - Merger Agreement [Member] $ in Thousands	3 Months Ended
	Sep. 30, 2020USD ($)
Consideration:
Consideration	$ 16,724
Cash	(969)
Other current assets	(11)
Property and equipment	(175)
Accounts payable and accrued liabilities	337
Milestone payment liability	188
In-process research and development	16,094
Warrant [Member]
Consideration:
Consideration	630
Common stock
Consideration:
Consideration	15,328
Success Fee Shares [Member]
Consideration:
Consideration	$ 766

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Loan payable, net of deferred loan costs		$ 441,000
Preferred stock, par value		$ 0.001		$ 0.001
Dividend payable		$ 2,000	$ 2,000
Related party payables		$ 382,004		$ 663,865
Preferred Stock Series A
Preferred Stock, shares issued		279,000		279,000
Preferred stock, rate of dividend	3.00%
Valent Technologies LLC [Member]
Loan payable, net of deferred loan costs	$ 278,530
Aggregate accrued interest	$ 28,530
Dividend payable		$ 2,089	$ 2,089
Valent Technologies LLC [Member] | Preferred Stock Series A
Preferred Stock, shares issued	278,530
Preferred stock, par value	$ 1

Loan from National Brain Tumo_3

Loan from National Brain Tumor Society and National Foundation for Cancer Research - Summary of Loan (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2020USD ($)
Guarantee Obligations [Line Items]
Interest expense	$ 8
Amortization of deferred loan costs	27
N B T S and N F C R [Member]
Guarantee Obligations [Line Items]
Funding	500
Financing costs	(94)
Interest expense	8
Amortization of deferred loan costs	27
Ending Balance	$ 441

Loan from National Brain Tumo_4

Loan from National Brain Tumor Society and National Foundation for Cancer Research - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Guarantee Obligations [Line Items]
Warrants exercised for cash	$ 994	$ 26
Warrant [Member]
Guarantee Obligations [Line Items]
Warrants exercise price	$ 30
National Brain Tumor Society and National Foundation for Cancer Research [Member]
Guarantee Obligations [Line Items]
Loan received	$ 500,000
National Brain Tumor Society [Member] | Warrant [Member]
Guarantee Obligations [Line Items]
Warrants issued	125,000
Warrants exercise price	$ 1.09
Warrants exercised for cash	$ 93,701
Risk-free interest rate	0.37%
Volatility Rate	89.82%
Expected Term	5 years
Dividend Rate	0.00%
National Brain Tumor Society [Member] | Promissory Note
Guarantee Obligations [Line Items]
Accrued interest rate	6.00%
Debt, maturity date	Jun. 19, 2021

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) - Preferred Stock Series C $ in Thousands	3 Months Ended
	Sep. 30, 2020USD ($)shares
Class Of Stock [Line Items]
Issuance | $	$ 18,355
Issuance, shares | shares	25,028
Ending Balance | $	$ 18,355
Ending Balance, shares | shares	25,028

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Aug. 16, 2019USD ($)$ / sharesshares	Sep. 30, 2014$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Aug. 19, 2021shares	Jun. 26, 2021shares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2016$ / sharesshares	Aug. 14, 2020shares
Class Of Stock [Line Items]
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance | $			$ 3,181,000
Net proceeds from private placement | $			$ 21,600,000
Convertible preferred stock			0				25,000
Preferred stock, par value | $ / shares			$ 0.001				$ 0.001
Underwritten public offering, description			the Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock (“2020 Investor Warrants”), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.
Common stock, shares issued			24,466,000				11,458,000
Warrants exercised for cash | $			$ 994,000	$ 26,000
Shares issued for services | $				5,000
Number of options granted			4,999,000
Total compensation expense | $			$ 405,000	$ 51,000
Stock options exercisable			828
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Number of shares available under the plan									6,700,000
Common stock, shares outstanding			164,235
Common stock, shares issued | $			$ 6,379,334,000
Common stock issued under the 2017 Plan			156,431
Percentage of fully diluted shares of common stock			8.00%
Number of options granted			222,584		155,734	66,850
Previous grants during the period			250,000
Common stock
Class Of Stock [Line Items]
Series B preferred stock dividend, shares			4,000	4,000
Conversion of Series B preferred stock to common stock, shares				6,000
Issued warrants to underwriters	4,895,000
Warrants exercise price | $ / shares	$ 0.001
Shares issued for services, shares			0	6,925
Shares issued for services | $			$ 0	$ 4,843
Pre-Funded Warrants
Class Of Stock [Line Items]
Issued warrants to underwriters	2,655,000
Warrants exercise price | $ / shares				$ 0.01
Issued warrants to underwriters				2,655,000
Warrants exercised for cash | $				$ 26,550,000
2020 Investor Warrant
Class Of Stock [Line Items]
Issued warrants to underwriters	7,762,500
Common stock, shares issued	800,000
Warrants To Purchase Common Stock1	1,012,500
Underwriting discounts and commissions amount | $	$ 6,582,966,000
Expiry date	Aug. 16, 2024
Placement Agent | 2020 Agent Warrants [Member]
Class Of Stock [Line Items]
Fair value disclosure | $			$ 3,300,000
Warrants outstanding, term			4 years
Director | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Total compensation expense | $			$ 319,376,000
Subject to Stockholder Approval | 2017 Omnibus Incentive Plan [Member] | Group Two
Class Of Stock [Line Items]
Stock options exercisable			250,000
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Number of options granted			4,758,687,000
Number of options expected to vest			4,278,687,000
Stock option vesting description			Of the total granted, 4,278,687 stock options vest as to 1/6 on the six month anniversary of the grant date with the remaining portion vesting in equal monthly installments over a period of 30 months commencing on the seven month anniversary of the grant date. Of the total stock options granted to executive officers and directors, 480,000 vest in 12 equal monthly installments beginning on October 15, 2020. All of the stock options granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions
Stock option term			10 years
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member] | Exercise Price of 1.70
Class Of Stock [Line Items]
Number of options granted			4,698,687,000
Stock option exercise price | $ / shares			$ 1.70
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member] | Exercise Price of 1.355
Class Of Stock [Line Items]
Stock option exercise price | $ / shares			$ 1.355
Number of options forfeited			60,000,000
Minimum | Director | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Exercise period			90 days
Maximum | Director | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Exercise period			1 year
Measurement Input, Risk Free Interest Rate | Placement Agent | 2020 Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input			0.27
Measurement Input, Price Volatility | Minimum | Placement Agent | 2020 Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input			95.2
Measurement Input, Price Volatility | Maximum | Placement Agent | 2020 Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input			95.8
Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services			25,028
Issuance, shares			25,028
Conversion of common stock, shares issued			21,516,484
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance | $			$ 3,180,000
Liquidation value | $			$ 25,028,000
Deferred financing costs | $							$ 84,944
Preferred stock, shares outstanding			25,028				0
Conversion of Series C preferred stock to common stock shares			21,516,484				0
Preferred Stock, shares issued			25,000				0
Preferred Stock Series C | Placement Agent | 2020 Agent Warrants [Member]
Class Of Stock [Line Items]
Conversion of common stock, shares issued			2,152,701
Shares issued of common stock for services			2,504
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares			$ 1.16
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares			1.214
Series C-3 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares			$ 1.15
Preferred Stock Series B
Class Of Stock [Line Items]
Conversion price | $ / shares								$ 32
Liquidation value | $			$ 5,200,000				$ 5,200,000
Shares issued of common stock for services								902,238
Preferred stock, shares outstanding			648,613				648,613
Purchase price of shares | $ / shares								$ 8
Convertible preferred stock								0.25
Bid price | $ / shares								$ 80
Final closing date								5 years
Preferred stock, rate of dividend								9.00%
Direct increase in accumulated deficit | $			$ 5,180				$ 2,046
Conversion of Series B preferred stock to common stock, shares			162,177				162,177
Preferred Stock, shares issued			649,000				649,000
Common stock
Class Of Stock [Line Items]
Series B preferred stock dividend, shares			3,700				3,700
Conversion of Series B preferred stock to common stock, shares			0				6,250
Preferred Stock Series A
Class Of Stock [Line Items]
Liquidation value | $			$ 278,530				$ 278,530
Preferred stock, shares outstanding			279,000				279,000
Preferred stock, rate of dividend		3.00%
Preferred Stock, shares issued			279,000				279,000
Change in preferred stock | $			$ 0	$ 0
Preferred Stock Series A | Exchange Agreement [Member]
Class Of Stock [Line Items]
Preferred stock, rate of dividend		3.00%
Preferred Stock, shares issued		278,530
Preferred stock, par value | $ / shares		$ 1
Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services			25,028
Issuance, shares			25,028
Cumulative dividends | $			$ 15,061,952
Total gross proceeds | $			25,000,000
Net proceeds from private placement | $			21,600,000
Deferred financing costs | $			$ 3,400,000
Private Placement [Member] | Series C Preferred Stock Warrants
Class Of Stock [Line Items]
Shares issued of common stock for services			2,504
Shares issued, price per share | $ / shares			$ 1,000
Issuance, shares			2,504
Underwriting Offering | 2020 Investor Warrant
Class Of Stock [Line Items]
Warrants exercise price | $ / shares	$ 1.15
Expiry date	Aug. 14, 2022
Issued warrants to underwriters	377,500,000
Underwriter warrants commencing date	Feb. 10, 2020
Merger Agreement [Member]
Class Of Stock [Line Items]
Dividend rate			0.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services			25,028
Shares issued, price per share | $ / shares			$ 1,000
Issuance, shares			25,028
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | First Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate			10.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Second Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate			15.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Third Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate			20.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate			25.00%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Outstanding Under the Legacy Plan (Detail)	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	4,999,000
Ending balance	6,544
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	1,559,000
Granted	4,999,000
Forfeited	(14,000)
Ending balance	6,544,000
Beginning balance | $ / shares	$ 4.61
Granted | $ / shares	1.68
Forfeited | $ / shares	1.42
Ending balance | $ / shares	$ 2.38

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	6,544
Stock options exercisable	828
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.61
Number of stock options outstanding	1,010
Weighted average remaining contractual life (years)	8 years 11 months 4 days
Stock options exercisable	566
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.74
Number of stock options outstanding	250
Weighted average remaining contractual life (years)	9 years 1 month 13 days
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.36
Number of stock options outstanding	300
Weighted average remaining contractual life (years)	9 years 11 months 23 days
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.70
Number of stock options outstanding	4,699
Weighted average remaining contractual life (years)	9 years 11 months 15 days
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 6.10
Number of stock options outstanding	30
Weighted average remaining contractual life (years)	8 years 1 month 9 days
Stock options exercisable	26
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 7
Number of stock options outstanding	3
Weighted average remaining contractual life (years)	7 years 8 months 23 days
Stock options exercisable	3
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 8.70
Number of stock options outstanding	12
Weighted average remaining contractual life (years)	7 years 1 month 2 days
Stock options exercisable	12
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 9.83
Number of stock options outstanding	83
Weighted average remaining contractual life (years)	7 years 7 months 20 days
Stock options exercisable	65
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 10.60
Number of stock options outstanding	4
Weighted average remaining contractual life (years)	7 years 6 months 14 days
Stock options exercisable	3
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 11.70
Number of stock options outstanding	30
Weighted average remaining contractual life (years)	2 years 4 months 28 days
Stock options exercisable	30
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 14.94
Number of stock options outstanding	3
Weighted average remaining contractual life (years)	1 year 8 months 1 day
Stock options exercisable	3
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 20
Number of stock options outstanding	13
Weighted average remaining contractual life (years)	1 year 7 days
Stock options exercisable	13
Exercise Price Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 21.10
Number of stock options outstanding	14
Weighted average remaining contractual life (years)	6 years 9 months 7 days
Stock options exercisable	14
Exercise Price Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 29.60
Number of stock options outstanding	5
Weighted average remaining contractual life (years)	4 years 4 months 6 days
Stock options exercisable	5
Exercise Price Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 37.60
Number of stock options outstanding	5
Weighted average remaining contractual life (years)	5 years 4 months 9 days
Stock options exercisable	5
Exercise Price Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 41
Number of stock options outstanding	4
Weighted average remaining contractual life (years)	6 years 1 month 9 days
Stock options exercisable	4
Exercise Price Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 42
Number of stock options outstanding	41
Weighted average remaining contractual life (years)	2 years 3 months 21 days
Stock options exercisable	41
Exercise Price Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 44.80
Number of stock options outstanding	3
Weighted average remaining contractual life (years)	5 years 4 months 9 days
Stock options exercisable	3
Exercise Price Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 49.50
Number of stock options outstanding	22
Weighted average remaining contractual life (years)	3 years 9 months 25 days
Stock options exercisable	22
Exercise Price Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 53.20
Number of stock options outstanding	8
Weighted average remaining contractual life (years)	5 years 7 months 6 days
Stock options exercisable	8
Exercise Price Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 61.60
Number of stock options outstanding	2
Weighted average remaining contractual life (years)	2 years 6 months
Stock options exercisable	2
Exercise Price Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 92
Number of stock options outstanding	3
Weighted average remaining contractual life (years)	2 years 8 months 1 day
Stock options exercisable	3

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model (Detail) - Stock options [Member]	3 Months Ended
	Sep. 30, 2020
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	121.00%
Risk-free rate	0.19%
Term - years	4 months 24 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	153.00%
Risk-free rate	0.42%
Term - years	5 years 9 months 18 days

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 405	$ 51
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	91	8
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 314	$ 43

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Unvested Stock Options (Detail)	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Equity [Abstract]
Beginning balance | shares	858,000
Granted | shares	4,999,000
Vested | shares	(127,000)
Forfeited | shares	(14,000)
Ending balance | shares	5,716,000
Beginning balance | $ / shares	$ 0.98
Granted | $ / shares	1.68
Vested | $ / shares	1.18
Forfeited | $ / shares	1.42
Ending balance | $ / shares	$ 1.59

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Warrants (Detail) - Common Stock Warrants [Member]	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Balance – June 30, 2020 | shares	10,309,000
Issuance of Adgero Warrants | shares	2,314,000
Exercise of warrants | shares	(994,000)	[1]
Warrants issued for services | shares	330,000	[2]
Expiry of warrants | shares	(101,000)	[3]
Balance – September 30, 2020 | shares	11,858,000
Beginning balance | $ / shares	$ 2.71
Issuance of Adgero Warrants | $ / shares	3.18
Stock option exercise price | $ / shares	1	[1]
Warrants issued for services | $ / shares	1.49	[2]
Expiry of warrants | $ / shares	30	[3]
Ending balance | $ / shares	$ 2.67
[1]	A total of 994,000 2020 Investor Warrants were exercised at $1.00 per share.
[2]	Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below.
[3]	The warrant expiries include the 2015 Investor Warrants, the 2015 Agent Warrants, and certain warrants issued for services. All of the expired warrants were exercisable at $30 per share.

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Warrants (Parenthetical) (Detail) - Warrant [Member]	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Warrants exercise price	$ 30
2020 Investor Warrant
Investor warrants exercised | shares	994,000
Warrants exercise price	$ 1

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Issued warrants to underwriters | shares	11,858,000
Warrants exercise price | $ / shares	$ 30
Issued For Services One [Member]
Issued warrants to underwriters | shares	25,000
Warrants exercise price | $ / shares	$ 30
Issued For Services One [Member] | Minimum
Expiry date	Dec. 1, 2020
Issued For Services One [Member] | Maximum
Expiry date	Feb. 1, 2021
Issued For Services Two [Member]
Issued warrants to underwriters | shares	6,000
Warrants exercise price | $ / shares	$ 17.80
Expiry date	Jan. 25, 2023
Issued For Services Three [Member]
Issued warrants to underwriters | shares	34,000
Warrants exercise price | $ / shares	$ 11.70
Expiry date	Feb. 27, 2023
Issued For Services Four [Member]
Issued warrants to underwriters | shares	14,000
Warrants exercise price | $ / shares	$ 9
Issued For Services Four [Member] | Minimum
Expiry date	Sep. 15, 2023
Issued For Services Four [Member] | Maximum
Expiry date	Oct. 11, 2023
Issued For Services Five [Member]
Issued warrants to underwriters | shares	280,000
Warrants exercise price | $ / shares	$ 0.75
Expiry date	Nov. 18, 2023
Issued For Services Six [Member]
Issued warrants to underwriters | shares	250,000
Warrants exercise price | $ / shares	$ 0.64
Expiry date	Jan. 20, 2024
Issued For Services Seven [Member]
Issued warrants to underwriters | shares	330,000
Warrants exercise price | $ / shares	$ 1.49
Expiry date	Sep. 22, 2023
Investor One [Member]
Issued warrants to underwriters | shares	6,744,000
Warrants exercise price | $ / shares	$ 1
Expiry date	Aug. 16, 2024
InvestorTwo [Member]
Issued warrants to underwriters | shares	760,000
Warrants exercise price | $ / shares	$ 3.10
Expiry date	Jun. 5, 2024
InvestorThree [Member]
Issued warrants to underwriters | shares	280,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 22, 2022
Investor Four
Issued warrants to underwriters | shares	208,000
Warrants exercise price | $ / shares	$ 35
Expiry date	Apr. 19, 2022
NBTS [Member]
Issued warrants to underwriters | shares	125,000
Warrants exercise price | $ / shares	$ 1.09
Expiry date	Jun. 19, 2025	[1]
Underwriting Offering [Member]
Issued warrants to underwriters | shares	377,000
Warrants exercise price | $ / shares	$ 1.15
Expiry date	Aug. 14, 2022
Agent [Member]
Issued warrants to underwriters | shares	47,000
Warrants exercise price | $ / shares	$ 3.88
Expiry date	Jun. 3, 2024
Agent One [Member]
Issued warrants to underwriters | shares	40,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 20, 2022
Agent Two [Member]
Issued warrants to underwriters | shares	14,000
Warrants exercise price | $ / shares	$ 40.60
Expiry date	Apr. 12, 2022
Agent Three [Member]
Issued warrants to underwriters | shares	10,000
Warrants exercise price | $ / shares	$ 40
Expiry date	May 12, 2021
Agent Four [Member]
Issued warrants to underwriters | shares	1,206,000
Warrants exercise price | $ / shares	$ 3.18
Expiry date	Apr. 8, 2021
Adgero Warrants One
Issued warrants to underwriters | shares	353,000
Warrants exercise price | $ / shares	$ 3.18
Expiry date	Aug. 31, 2021
Adgero Warrants Two
Issued warrants to underwriters | shares	755,000
Warrants exercise price | $ / shares	$ 3.18
Expiry date	Jan. 17, 2022
[1]	NBTS Warrants were issued in connection with respect to the NBTS Loan (note 5).

Stockholders' Equity - Schedu_9

Stockholders' Equity - Schedule of Outstanding Series C Preferred Stock Warrants (Detail) - Series C Warrants [Member]	Sep. 30, 2020$ / sharesshares
Issued warrants to underwriters	2,504
Issuance of Preferred Series C-1 Warrants
Issued warrants to underwriters	1,959
Warrants exercise price | $ / shares	$ 1.16
Issuance of Preferred Series C-2 Warrants
Issued warrants to underwriters	219
Warrants exercise price | $ / shares	$ 1.21
Issuance of Preferred Series C-3 Warrants
Issued warrants to underwriters	326
Warrants exercise price | $ / shares	$ 1.15

Stockholders' Equity - Sched_10

Stockholders' Equity - Schedule of Outstanding Series C Warrants (Detail) - Series C Warrants [Member]	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Issued warrants to underwriters	2,504
Number of conversion shares	2,152,000
Cumulative common stock dividends	1,506,000
Series 1 Warrants Outstanding
Issued warrants to underwriters	1,959
Warrants exercise price | $ / shares	$ 1.16
Number of conversion shares	1,689,000
Cumulative common stock dividends	1,182,000
Series 2 Warrants Outstanding Member
Issued warrants to underwriters	219
Warrants exercise price | $ / shares	$ 1.21
Number of conversion shares	180,000
Cumulative common stock dividends	126,000
Series 3 Warrants Outstanding
Issued warrants to underwriters	326
Warrants exercise price | $ / shares	$ 1.15
Number of conversion shares	283,000
Cumulative common stock dividends	198,000

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Series B Preferred stock dividend	$ 5	$ 2
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance	3,181
Non-cash issue costs (note 6)	3,287
Issue costs in accounts payable (note 6)	$ 193

Financial Instruments (Details)

Financial Instruments (Details) $ in Thousands	Sep. 30, 2020USD ($)
Investments All Other Investments [Abstract]
Loans Payable, Fair Value Disclosure	$ 508,466

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 31, 2020	Aug. 19, 2021
Subsequent Event [Line Items]
Warrants issued	161,084
Warrants exercise price	$ 1
Gross proceeds from the exercise and exchange of warrants	$ 161,084
Stock options [Member]
Subsequent Event [Line Items]
Number of options exercised	35,000
Stock option exercise price	$ 0.61
Gross proceeds from stock options exercised	$ 21,350
Stock Option Amendments [Member] | Executive Officers [Member]
Subsequent Event [Line Items]
Stock option exercise price		$ 0.61
Acceleration of vesting of stock options to purchase shares		279,675